A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design

Theoretical Biology and Medical Modelling

Volumn 10, Issue 1, 2013, Pages

  Kapoor, Suhela ^a   Rallabandi, V P Subramanyam ^a   Sakode, Chandrashekhar ^b   Padhi, Radhakant ^b   Roy, Prasun K ^a  

^a NATIONAL BRAIN RESEARCH CENTRE   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Astrocytoma; Cancer therapy optimization; Chemotherapy; Control system; Glioblastoma; Glioma; Immunotherapy; Meningioma; Oligodendroglioma; Tumour cell extinction

Indexed keywords

ANIMALIA;

ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE;

ARTICLE; CANCER GRADING; COMPUTER SIMULATION; DOSE RESPONSE; GLIOMA; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; REMISSION; TRANSLATIONAL RESEARCH;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; COMPUTER SIMULATION; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOMA; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; MAGNETIC RESONANCE IMAGING; NEOPLASM GRADING; NEOPLASMS; REMISSION INDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84890916925     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-10-68     Document Type: Article

References (50)

1. Perry M, The Chemotherapy Source Book Philadelphia: Lippincott 3 2001
2. Murphy G, Lawrence W, Lenhard R: American Cancer Society Textbook of Clinical Oncology American Cancer Society: Atlanta 1995
3. Phase I trial of temozolomide. Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH, Gibson AC, Br J Cancer 1992 65 287 291 10.1038/bjc.1992.57 1739631
4. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Wheeler C, Asha D, Gentao L, et al. Clin Cancer Res 2004 10 5316 5326 10.1158/1078-0432.CCR-04-0497 15328167 (Pubitemid 39100466)
5. Immunotherapeutic Strategies for Malignant Glioma. Fenstermaker R, Ciesielski M, Cancer Control 2004 11 3 181 191 15153842 (Pubitemid 38758223)
6. Immune recovery in children with malignancy after cessation of chemotherapy. Mustafa M, Buchanan G, Winick N, J Pediatr Hematol Oncol 1998 20 5 451 457 10.1097/00043426-199809000-00008 9787318 (Pubitemid 29133200)
7. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Nanda S, Moore H, Lenhart S, Math Biosci 2007 210 143 156 10.1016/j.mbs.2007.05.003 17599363 (Pubitemid 47562486)
8. Cellular immunotherapy for high grade glioma: Mathematical analysis deriving efficacious infusion rates based on patient requirements. Kogan Y, Forys U, Shukron O, et al. SIAM Jour Appl Math 2010 70 1953 1976 10.1137/08073740X
9. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Kuznetsov V, Makalkin I, Taylor M, Perelson A, Bull Math Biol 1994 56 295 321 8186756
10. Modeling immunotherapy of the tumor-immune interaction. Kirschner D, Panetta J, J Math Biol 1998 37 235 252 10.1007/s002850050127 9785481
11. From neurocomputation to immunocomputation: Model and algorithm for fluctuation-induced instability in biological systems. Roy P, Kozma R, Majumder D, IEEE Trans. Evol. Computation 2002 9 3 292 305 (Pubitemid 34867251)
12. Beyond the oncogene paradigm: understanding complexity in cancerogenesis. Bizzari M, Cucina A, D'Anselmi F, Acta Biotheor 2008 56 173 196 10.1007/s10441-008-9047-8 18288572
13. Kafarov V, Cybernetic methods in chemistry and chemical engineering Moscow: Science Publishers 1986
14. Automatic path planning and control design for UAV using dynamic inversion. Singh S, Padhi R, Proc. Amer. Control Conf St. Louis: American Automatic Control Council 2009 2409 2414
15. Khalil H, Nonlinear Control Systems Prentice Hall: Princeton 1996 1996
16. An optimal dynamic inversion-based neuro-adaptive approach for treatment of chronic myelogenous leukemia. Padhi R, Kothari M, Comp Methods and Prog in Biomed 2007 87 3 208 224 10.1016/j.cmpb.2007.05.011 (Pubitemid 47212593)
17. Development and analysis of a feedback treatment strategy for parturient paresis of cows. Padhi R, Balakrishnan S, IEEE Trans. Control Systems Tech 2004 12 1 52 64 10.1109/TCST.2003.821962
18. Mixed immunotherapy and chemotherapy of tumor: Modeling, application and biological interpretations. de Pillis L, Gu W, Radunskaya A, J Theor Biol 2006 238 841 862 10.1016/j.jtbi.2005.06.037 16153659 (Pubitemid 43175834)
19. A validated mathematical model of cell-mediated immune response to tumor growth. de Pillis L, Radunskaya A, Wiseman C, Cancer Res 2005 65 17 7950 7958 16140967 (Pubitemid 41297274)
20. Calabresi P, Schein P, Medical Oncology: Basic Principles and Clinical Management of Cancer New York: McGraw-Hill 2 1993
21. Cell death and the maintenance of immunological memory. Yates A, Callard R, Discrete & Contininous Dynamical Systems 2002 1 43 59
22. Dynamics of T-lymphocyte responses: intermediates, effectors, and memory cells. Lanzavecchia A, Sallusto F, Science 2000 290 92 97 10.1126/science.290. 5489.92 11021806
23. A mathematical model of gliobalstoma tumor spheroid invasion in a 3D in vitro experiment. Stein A, Demuth T, Mobley D, et al. Biophys J 2007 92 356 365 10.1529/biophysj.106.093468 17040992 (Pubitemid 46048443)
24. The Rael and H60 ligands of NKG2D receptor simulate tumor immunity. Diefenbach A, Jensen E, Jamieson A, Raulet D, Nature 2001 413 165 171 10.1038/35093109 11557981 (Pubitemid 32867877)
25. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Dudley M, Wunderlich J, Robbins P, et al. Science 2002 298 850 854 10.1126/science.1076514 12242449 (Pubitemid 35231542)
26. Lymphocytosis. Macintyre E, Linch D, Postgrad Medical J 1988 64 42 47 10.1136/pgmj.64.747.42
27. The NK cells in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma after intensive chemotherapy. Jarosz M, Hak L, Wieckiewicz J, Mysliwska J, Central Eur J Immunol 2009 34 2 94 99
28. Lymphocyte subsets in term and significantly preterm UK infants. Berrington J, Barge D, Spickett G, Clin Exp Immunol 2005 140 2 289 292.445 10.1111/j.1365-2249.2005.02767.x 15807853 (Pubitemid 40559155)
29. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA. Jawahar S, Moody C, Chan M, Chatila T, Clin Exp Immunol 1996 103 408 413 8608639 (Pubitemid 26089945)
30. Roitt I, Brostoff J, Male D, Immunology St. Louis: Mosby 1993
31. Zotin A, Thermodynamic Bases of Biological Processes New York: Walter de Gruyter Press 1990
32. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Ueno T, Ko S, Grubbs E, et al. Mol Cancer Ther 2000 5 732 738
33. Intracerebral vs. subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of glioma and melanoma. Glick R, Lichtor T, Mogharbel A, Neurosurgery 1997 41 898 907 10.1097/00006123-199710000-00025 9316052 (Pubitemid 27422118)
34. Mathematical model for chemotherapeutic drug efficacy in arresting tumour growth based on the cancer stem cell hypothesis. Ganguly R, Puri I, Cell Prolif 2000 40 338 354
35. Dynamics of chronic myeloid leukaemia. Michor F, Hughes T, Iwasa Y, Nature 2005 435 1267 7031 10.1038/nature03669 15988530 (Pubitemid 40943094)
36. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside CNS. Ewend M, Thompson R, Anderson R, J Immunotherapy 2000 23 4 438 448 10.1097/00002371-200007000-00007 (Pubitemid 30457701)
37. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS, Hong YK, Clin Vaccine Immunol 2010 17 1 143 153 10.1128/CVI.00292-09 19889936
38. Myeloablative temozolomide enhances CD8§ssup§+§esup§ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, et al. PlosOne 2013 8 3 59082 10.1371/journal.pone.0059082
39. Multifaceted oncolytic virus therapy for gliobalstoma in an immunocompetent cancer stem cell model. Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jayaretna DS, Martuza RL, Rabkin SD, Proc Natl Acad Sci U S A 2013 110 29 12006 12011 10.1073/pnas.1307935110 23754388
40. Long-term remission of malignant brain tumors. Bowles A, Perkins E, Neurosurgery 1999 44 3 636 642 10.1097/00006123-199903000-00110 10069601
41. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Lasky JL 3rd, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB, Anticancer Res 2013 33 5 2047 2056 23645755
42. Amide proton transfer imaging of human brain tumors at 3 Tesla. Jones C, Schlosser M, van Zijl P, Magnetic Reson Med 2006 56 585 592 10.1002/mrm.20989 (Pubitemid 44338877)
43. State and parameter estimation of the heat shock response system using Kalman and particle filters. Niranjan M, Liu X, Bioinformatics 2012 28 1501 1507 10.1093/bioinformatics/bts161 22539674
44. An improved constraint filtering technique for inferring hidden states and parameters of a biological model. Baker S, Poskar C, Schreiber F, Junker B, Bioinformatics 2013 29 8 1052 1059 10.1093/bioinformatics/btt097 23434837
45. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Hidalgo M, Bruckheimer E, Rajeshkumar N, Mol Cancer Therapy 2011 10 8 1311 1316 10.1158/1535-7163.MCT-11-0233
46. Use of tumour-responsive T-cells as cancer treatment. Disis M, Bernhard H, Jaffee E, Lancet 2009 373 673 683 10.1016/S0140-6736(09)60404-9 19231634
47. Letter to the Editor. Monte U, Cell Cycle 2009 8 3 505 506 10.4161/cc.8.3.7608 19176997
48. Mechanisms involved in natural killer cell mediated target cell death leading to spontaneous tumour regression. Khar A, J Bioscience 1997 22 1 23 31 10.1007/BF02703615 (Pubitemid 27344992)
49. Transforming growth factor β pathway serves as a primary tumor suppressor in CD8+ T-cell tumorigenesis. Lucas P, McNeil N, Hilgenfeld E, Gress R, Cancer Res 2004 64 6524 6529 10.1158/0008-5472.CAN-04-0896 15374963 (Pubitemid 39297909)
50. Exhaustion of tumor-specific CD8 + T cells in metastases from melanoma patients. Baitsch L, Baumgaertner P, Devevre E, Speiser D, J Clin Invest 2011 121 6 2350 2360 10.1172/JCI46102 21555851